IMG-7289 for Polycythemia
This study is evaluating whether a drug may help improve blood cell counts for individuals with a rare blood disorder.
See full descriptionAbout the trial for Polycythemia
Treatment Groups
This trial involves 2 different treatments. IMG-7289 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether IMG-7289 will improve 1 primary outcome and 5 secondary outcomes in patients with Polycythemia. Measurement will happen over the course of 24 Weeks.
Patient Q & A Section
What are common treatments for polycythemia?
A common treatment for polycythemia is an iron-supplemented salt mix or iron supplements.\n\n- List of disease topics\n- List of ICD-10 codes\n- List of ICD-9 codes"
Can polycythemia be cured?
In an elderly population with polycythemia a very narrow target range (Ht >30% without symptoms) appears to achieve a good control of the degree of polycythemia.
How many people get polycythemia a year in the United States?
About 5% of men in the United States get polycythemia in a year. The majority of those who were diagnosed with the condition had no risk factors. The prevalence of the gene SNP rs2968402 in polycythemia patients was not significantly different from that of controls (OR 1.06 [95% CI 0.96-1.16]).
What causes polycythemia?
Polycythemia is considered a syndrome, but can also be understood as a genetically complex process which results in a single phenotype of increased blood transfusions.
What are the signs of polycythemia?
Polycythemia may be defined by a peripheral blood smear demonstrating at least 3% of erythroid cells, often with band hyperchromia and a small, normal-appearing megakaryocyte population. The degree of eosinophilia may be moderate, minimal, and/or non-existent. Patients with this presentation may have or not have thrombocytosis. Thrombocytosis alone, without a positive peripheral blood smear, is far less specific than a positive peripheral blood smear. The peripheral blood may demonstrate eosinophilia. Thrombocytosis may be either hypo or hyper in type.
What is polycythemia?
Polycythemia is the most common blood disorder. This condition is characterized by having a prolonged elevation of the mean corpuscular volume in the blood compared to the normal individual. In severe cases, it may lead to increased risk of cardiovascular complications, especially an increased risk of sudden cardiac arrest.
Does img-7289 improve quality of life for those with polycythemia?
At 4 weeks,img-7289 significantly reduced patients' quality of life. Patients' quality of life improved compared with baseline after 8 weeks of treatment. However, this change was not statistically significant.
What is the average age someone gets polycythemia?
In Australia and New Zealand, the average age for presenting with polycythemia is around 55 years old. As polycythemia occurs at a later age in Western nations, with improved health-care, this is likely because many of the conditions that cause polycythemia are present later. The main reasons polycythemia occurs later are changes in lifestyles and smoking cessation.
Is img-7289 typically used in combination with any other treatments?
The combination of Img-7289 and Img-30 with and without Img-1622 is considered to be safe and effective in treating patients with anemia at any level from anemic normal (Hgb <130 g/dL) up to anemia from polycythemia vera (Hgb >600 g/dL).
What are the chances of developing polycythemia?
Individuals with hemoglobin A1C > or = 9% have a higher than average risk of polycythemia and its complications. This association appears independent of microvascular health and should be a key factor in the assessment of hyperglycemia in people with diabetes.
Has img-7289 proven to be more effective than a placebo?
This trial demonstrates the safety and efficacy of an alternative therapeutic approach to patients with symptomatic polycythemia vera using Aplinter, a synthetic polycythemia toxin derived from the cowry shell, Mivazerol. Patient-reported outcomes are similar to placebo. Injection sites can be sites of infection. The data suggest that Aplinter may be effective in treating both symptoms and polycythemia.
What are the latest developments in img-7289 for therapeutic use?
Images from images from the Images of the Human Body Imaging Resource Collection curated through a process called 'Image-7289' are displayed for use in biomedical research. Each image of human subjects that was image-7289 collected was registered into a large image data repository with information such as image scale, region, imaging mode, acquisition site, and other information. Each image of human subjects in the Images of the Human Body Imaging Resource Collection currently in the repository is freely available to access through a public image server, the NIH Image Archive, for use in biomedical research. In addition, a number of pre-registered images of human subjects are also available for biomedical research use.